FDA Panel Approves Novo Nordisk Diabetes Drug

Oct 18, 2017

Reuters

The conclusion of an advisory panel to the U.S. FDA concluded was that Novo Nordisk A/S’s new diabetes drug semaglutide was effective, reasonably safe and should be approved, according to a Reuters article.

The panel reportedly voted 16-0 with one abstention recommending the drug's approval. The drug falls in a class of glucagon-like peptide-1 (GLP-1) analogs, which imitate an intestinal hormone that stimulates the production of insulin.

Read the full story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments